According to the latest report by IMARC Group, The Indian diabetes market reached a value of US$ 2,282 Million in 2019. Looking forward, the market is expected to witness strong growth during 2020-2025.
Diabetes is a chronic disease caused by improper production of or response to insulin in the body which causes high blood sugar levels. Uncontrolled diabetes can result in a variety of complications, such as visual, cardiovascular, renal and neural disorders. The heightening obesity rates, rising stress levels and lack of proper exercise are the major causes of diabetes in India. In order to control the damage caused by the increasing cases of diabetes in the country, the Indian Government is taking initiatives to provide free treatment and insulin to diabetics at government hospitals.
Request to get the sample report: https://www.imarcgroup.com/india-diabetes/requestsample
The growing awareness among consumers regarding the symptoms of diabetes and its adverse health effects have largely intensified the diagnosis and drug treatment rates in the country. This is the major growth-driving factor for the diabetes market in India. Some of the other factors contributing to the market growth are rapid urbanization, developing healthcare infrastructure, low-cost of drug production, accelerating pharmaceutical contract manufacturing and introduction of advanced technologies. However, high research and development costs, stringent pricing policy, technological developments that make the existing drugs unmarketable or obsolete, and regulatory approvals in terms of quality control, price control and IPR (Intellectual Property Rights) protection are the major factors hampering the market growth.
The report has also examined the competitive landscape of diabetes market in Japan.
- Novo Nordisk A/S (NVO)
- Eli Lilly and Company (LLY)
- Sanofi (SNY)
- BIOCON LTD. (BIOCON.BO)
- WOCKHARDT LTD. (WOCKPHARMA.BO)
Key Insights from the market
- On the basis of type, the market has been segmented into type-1 and type-2 diabetes. Currently, type-2 diabetes accounts for the maximum share.
- On the basis of region, the market has been segregated into urban and rural regions. The prevalence of diabetes in the urban population is much higher as opposed to the rural areas.
- Based on gender, the market has been classified into males and females. Amongst these, the prevalence of diabetes in males is higher in comparison with females.
- On the basis of age group, age group of 40-59 years holds the largest share of the diabetes population in India. It is followed by age group of 60-79 years and 20-39 years.
Browse full report with detailed TOC and list of figures and tables: https://www.imarcgroup.com/india-diabetes
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800